stockportfolio.pro
ABT vs NVS: Which Stock Is the Better Buy?
Abbott Laboratories and Novartis AG side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — ABT vs NVS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Abbott Laboratories (ABT) | Novartis AG (NVS) | |
|---|---|---|
| Market cap | $166.2B | $290.6B |
| Revenue (latest FY) | $44.33B | $56.67B |
| Net income (latest FY) | $6.52B | $13.98B |
| Revenue growth (5y CAGR) | 5.1% | 9.3% |
| Net margin | 14.7% | 24.7% |
| Return on equity | 12.5% | 30.3% |
| P/E ratio | 26.7 | 21.8 |
| Dividend yield | 2.6% | 3.2% |
| Profitable years (of last 10) | 10 | 4 |
| Positive free cash flow | Yes | Yes |
See the full ABT vs NVS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open ABT's full financials → Open NVS's full financials →Frequently asked questions
Which is bigger, ABT or NVS?
Novartis AG is larger by market capitalization — $290.6B versus $166.2B.
Which grows faster, ABT or NVS?
Over the last five fiscal years, Novartis AG grew revenue faster — 9.3%/yr versus 5.1%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.